Cue Biopharma, Inc. (CUE) vs Nkarta, Inc. (NKTX)

Cue Biopharma, Inc. and Nkarta, Inc. are both Biotechnology companies. Cue Biopharma, Inc. and Nkarta, Inc. are of similar size ($138.2M and $135.6M). Nkarta, Inc. has the higher net margin (0.00% vs −435.8%) and the lower return on invested capital (−127.2% vs 0.00%). Across the 13 metrics below, Nkarta, Inc. leads on 8 and Cue Biopharma, Inc. on 5.

Valuation

Metric CUE NKTX Biotechnology median
P/E n/m n/m 8.42
P/S 3.14 n/m 10.01
P/B 51.25 0.58 2.21
Price to free cash flow n/m n/m 21.01
EV/EBITDA n/m 0.31 0.61
EV/Sales 2.73 n/m 9.41
Earnings yield (144.73%) (81.35%) (31.85%)
Free cash flow yield (42.34%) (65.31%) (24.58%)

Profitability

Metric CUE NKTX Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (262.03%) 0.00% 0.00%
Net margin (435.83%) 0.00% 0.00%
Free cash flow margin (133.13%) 0.00% 0.00%
Return on equity (1,603.48%) (38.76%) (56.36%)
Return on assets (459.60%) (29.86%) (48.04%)
Return on invested capital 0.00% (127.22%) 0.00%

Growth

Metric CUE NKTX Biotechnology median
Revenue growth (TTM) 354.37% — 6.02%
EPS growth (last fiscal year) 61.11% 11.88% 30.26%
Revenue growth, 5-year CAGR 54.16% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CUE NKTX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 1.25 7.98 4.72
Net debt to EBITDA 1.10 2.35 0.96

Dividend

Metric CUE NKTX Biotechnology median
Dividend yield — — 0.08%
Payout ratio — — —

Size

Metric CUE NKTX Biotechnology median
Market cap 135.63m 138.24m 132.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack